Pilot hepatitis C micro-elimination strategy in Pakistani migrants in Catalonia through a community intervention
Por:
Martro, E, Ouaarab, H, Saludes, V, Buti, M, Trevino, B, Roade, L, Egea-Cortes, L, Reyes-Urena, J, Not, A, Majo, X, Colom, J and Prat, JGI
Publicada:
1 ago 2022
Ahead of Print:
1 jun 2022
Resumen:
Background and Aims Pakistani migrants in Catalonia, Spain, could have high hepatitis C virus (HCV) prevalence. The aims of the HepClink study were (i) to implement and assess the quality of a micro-elimination strategy based on a community intervention and (ii) to obtain data from primary care (PC) registries as a baseline comparator. Methods The community intervention targeted Pakistani adults and consisted of education, screening and simplified access to treatment. Quality indicators were calculated (effectiveness, impact and acceptability). The testing rate, the prevalence of HCV antibodies and HCV-RNA were compared with those observed in the Pakistani population accessing PC in the previous year. Results A total of 505 participants were recruited through the community intervention (64.6% men, median 37 years) vs those accessing PC (N = 25 455, 70.9% men, median 38 years). Among study participants, 35.1% did not know about HCV and 9.7% had been previously tested. The testing rate in the community intervention was 99.4% vs 50.7% in PC. Prevalence was 4.6% vs 7.1% (p = .008) for HCV antibodies and 1.4% (3/6 new diagnoses) vs 2.4% (p = .183) for HCV-RNA. Among the six viremic patients, three began treatment within the intervention and two through the usual circuit and all completed the full course. Conclusions This novel community intervention was well accepted and effective at reaching a Pakistani migrant population with a low-level knowledge of HCV and largely not tested before. The observed prevalence and the high unawareness of their HCV status justify a targeted screening in this group both in the community and in PC.
Filiaciones:
:
Hosp Badalona Germans Trias & Pujol, Inst Invest Germans Trias & Pujol IGTP, Microbiol Dept, Lab Clin Metropolitana Nord, Badalona, Barcelona, Spain
Inst Salud Carlos III, Consorcio Invest Biomed Red Epidemiol & Salud Pub, Madrid, Spain
Ouaarab, H:
Drassanes Vall dHebron Ctr Int Hlth & Infect Dis, Community & Publ Hlth Team ESPIC, Barcelona, Spain
:
Hosp Badalona Germans Trias & Pujol, Inst Invest Germans Trias & Pujol IGTP, Microbiol Dept, Lab Clin Metropolitana Nord, Badalona, Barcelona, Spain
Inst Salud Carlos III, Consorcio Invest Biomed Red Epidemiol & Salud Pub, Madrid, Spain
Buti, M:
Hosp Univ Vall dHebron, Liver Unit, Internal Med Dept, Barcelona, Spain
Inst Salud Carlos III, CIBER Enfermedades Hepat & Digest CIBERehd, Madrid, Spain
Trevino, B:
Drassanes Vall dHebron Ctr Int Hlth & Infect Dis, Barcelona, Spain
Roade, L:
Hosp Univ Vall dHebron, Liver Unit, Internal Med Dept, Barcelona, Spain
Egea-Cortes, L:
Generalitat Catalunya, Ctr Estudis Epidemiol Infecc Transmissio Sexual S, Dept Salut, Badalona, Barcelona, Spain
:
Inst Salud Carlos III, Consorcio Invest Biomed Red Epidemiol & Salud Pub, Madrid, Spain
Generalitat Catalunya, Ctr Estudis Epidemiol Infecc Transmissio Sexual S, Dept Salut, Badalona, Barcelona, Spain
:
Hosp Badalona Germans Trias & Pujol, Inst Invest Germans Trias & Pujol IGTP, Microbiol Dept, Lab Clin Metropolitana Nord, Badalona, Barcelona, Spain
Majo, X:
Publ Hlth Agcy Catalonia, Programa Prevencio Control & Atencio Virus Immuno, Barcelona, Spain
Colom, J:
Publ Hlth Agcy Catalonia, Programa Prevencio Control & Atencio Virus Immuno, Barcelona, Spain
Prat, JGI:
Drassanes Vall dHebron Ctr Int Hlth & Infect Dis, Community & Publ Hlth Team ESPIC, Barcelona, Spain
|